Trial Profile
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Status:
Discontinued
Phase of Trial:
Phase 0
Latest Information Update: 20 May 2022
Price :
$35
*
At a glance
- Drugs REC 2282 (Primary)
- Indications Meningioma; Neurilemmoma
- Focus Proof of concept; Therapeutic Use
- 22 Feb 2022 Status changed from active, no longer recruiting to discontinued because of drug manufacturing logistics and lack of access to drug supply.
- 06 May 2020 Planned End Date changed from 1 Oct 2020 to 1 Oct 2023.
- 06 May 2020 Planned primary completion date changed from 1 Oct 2020 to 1 Oct 2021.